Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis

European Journal of Surgical Oncology

Volumn 37, Issue 3, 2011, Pages 187-198

  Cooper, K L ^a   Harnan, S ^a   Meng, Y ^a   Ward, S E ^a   Fitzgerald, P ^a   Papaioannou, D ^a   Wyld, L ^b,c   Ingram, C ^b,c   Wilkinson, I D ^b,c   Lorenz, E ^b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Axilla; Breast cancer; Diagnostic; Meta analysis; Positron emission tomography; Systematic review

Indexed keywords

AXILLARY LYMPH NODE; AXILLARY MASS; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; META ANALYSIS; MICROMETASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79851513300     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.01.003     Document Type: Review

References (68)

1. A.D. Purushotham, S. Upponi, and M.B. Klevesath Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial J Clin Oncol 23 2005 4312 4321 (Pubitemid 46209968)
2. D.K. Blanchard, J.H. Donohue, C. Reynolds, and C.S. Grant Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer Arch Surg 138 2003 482 487
3. R.E. Mansel, L. Fallowfield, and M. Kissin Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial J Natl Cancer Inst 98 2006 599 609 (Pubitemid 43904843)
4. R. Crane-Okada, R.A. Wascher, D. Elashoff, and A.E. Giuliano Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer Ann Surg Oncol 15 2008 1996 2005
5. S.A. McLaughlin, M.J. Wright, and K.T. Morris Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements J Clin Oncol 26 2008 5213 5219
6. S. Alvarez, E. Anorbe, P. Alcorta, F. Lopez, I. Alonso, and J. Cortes Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review AJR Am J Roentgenol 186 2006 1342 1348 (Pubitemid 46112571)
7. National Institute for Health and Clinical Excellence (NICE) and National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment; 2009.
8. E. Brogi, E. Torres-Matundan, L.K. Tan, and H.S. Cody III The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients Ann Surg Oncol 12 2005 173 180 (Pubitemid 40486627)
9. P.J. van Diest, H. Torrenga, and P.J. Borgstein Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer Histopathology 35 1999 14 18 (Pubitemid 29325292)
10. G. Viale, P. Dell'Orto, and M.O. Biasi Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription- polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients Ann Surg 247 2008 136 142
11. P. Blumencranz, P.W. Whitworth, and K. Deck Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors Am J Surg 194 2007 426 432 (Pubitemid 47370997)
12. J.A. Olson Jr., L.M. McCall, and P. Beitsch Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011 J Clin Oncol 26 2008 3530 3535
13. C.Q. Liu, Y. Guo, J.Y. Shi, and Y. Sheng Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review Eur J Cancer 45 2009 1560 1568
14. L.G. Wilke, L.M. McCall, and K.E. Posther Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial Ann Surg Oncol 13 2006 491 500
15. J.R. Benson, and G.C. Wishart Is intra-operative nodal assessment essential in a modern breast practice? Eur J Surg Oncol 36 2010 1162 1164
16. K. Facey, I. Bradbury, G. Laking, and E. Payne Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers Health Technol Assess 11 iii 2007 85
17. S.R. Cherry The 2006 Henry N. Wagner Lecture: of mice and men (and positrons)-advances in PET imaging technology J Nucl Med 47 2006 1735 1745 (Pubitemid 47545014)
18. C. Messa, V. Bettinardi, and M. Picchio PET/CT in diagnostic oncology Q J Nucl Med Mol Imaging 48 2004 66 75 (Pubitemid 39248295)
19. D.A. Podoloff, R.H. Advani, and C. Allred NCCN task force report: positron emission tomography (PET)/Computed tomography (CT) scanning in cancer JNCCN J Natl Compr Cancer Netw 5 2007 S1 S22
20. N.C. Hodgson, and K.Y. Gulenchyn Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26 2008 712 720 (Pubitemid 351264383)
21. J.S. Sloka, P.D. Hollett, and M. Mathews A quantitative review of the use of FDG-PET in the axillary staging of breast cancer Med Sci Monitor 13 2007 RA37 RA46
22. Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, Papaioannou D et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in breast cancer: systematic review and economic evaluation. Health Technol Assess, in press.
23. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 W64
24. PRISMA statement website 2009 www.prisma-statement.org
25. Cancer Research UK TNM breast cancer staging 2009 http://www.cancerhelp. org.uk/help/default.asp?page=3316
26. Agency for Healthcare Research and Quality (AHRQ) Surgery Choices for women with early-stage breast cancer 2009 http://www.ahrq.gov/consumer/ brcanchoice.htm
27. US National Cancer Institute (NCI) Surgery choices for women with early-stage breast cancer 2009 http://www.cancer.gov/cancertopics/breast-cancer- surgery-choices
28. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 2003 25
29. J.B. Reitsma, A.S. Glas, A.W. Rutjes, R.J. Scholten, P.M. Bossuyt, and A.H. Zwinderman Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews J Clin Epidemiol 58 2005 982 990 (Pubitemid 41316441)
30. M.M. Leeflang, Y.J. bets-Ossenkopp, and C.E. Visser Galactomannan detection for invasive aspergillosis in immunocompromized patients Cochrane Database Syst Rev 2008 CD007394
31. B.J. Chae, J.S. Bae, B.J. Kang, S.H. Kim, S.S. Jung, and B.J. Song Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer Jpn J Clin Oncol 39 2009 284 289
32. T.A. Heusner, S. Kuemmel, and S. Hahn Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients Eur J Nucl Med Mol Imaging 2009
33. J. Kim, J. Lee, and E. Chang Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience World J Surg 33 2009 943 949
34. N. Taira, S. Ohsumi, and D. Takabatake Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging Jpn J Clin Oncol 39 2009 16 21
35. D. Fuster, J. Duch, and P. Paredes Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures J Clin Oncol 26 2008 4746 4751
36. S. Ueda, H. Tsuda, and H. Asakawa Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer BMC Cancer 8 2008 165
37. U. Veronesi, C.C. De, and V.E. Galimberti A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann Oncol 18 2007 473 478 (Pubitemid 46359625)
38. T.F. Cermik, A. Mavi, S. Basu, and A. Alavi Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer Eur J Nucl Med Mol Imaging 35 2008 475 483 [see comment] (Pubitemid 351661670)
39. A. Gil-Rendo, G. Zornoza, M.J. Garcia-Velloso, F.M. Regueira, C. Beorlegui, and M. Cervera Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer Br J Surg 93 2006 707 712 (Pubitemid 43886022)
40. L. Weir, D. Worsley, and V. Bernstein The value of FDG positron emission tomography in the management of patients with breast cancer. [Review] [20 refs] Breast J 11 2005 204 209 (Pubitemid 40664065)
41. R. Agresti, F. Crippa, and A. Gerali Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches EJC Supplements 2004 2
42. M.K. Fehr, R. Hornung, and Z. Varga Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy Breast J 10 2004 89 93 [see comment] (Pubitemid 38375027)
43. T. Inoue, K. Yutani, T. Taguchi, Y. Tamaki, E. Shiba, and S. Noguchi Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography J Cancer Res Clin Oncol 130 2004 273 278 (Pubitemid 38680268)
44. P.J. Lovrics, V. Chen, and G. Coates A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer Ann Surg Oncol 11 2004 846 853 [see comment]
45. R.L. Wahl, B.A. Siegel, R.E. Coleman, C.G. Gatsonis PET Study Group Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 2004 277 285 (Pubitemid 41095092)
46. E. Barranger, D. Grahek, M. Antoine, F. Montravers, J.N. Talbot, and S. Uzan Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer Ann Surg Oncol 10 2003 622 627 (Pubitemid 40486893)
47. U. Guller, E.U. Nitzsche, and U. Schirp Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71 2002 171 173 (Pubitemid 34145374)
48. Y. Nakamoto, A.E. Chang, and K.R. Zasadny Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer Mol Imaging Biol 4 2002 161 169 (Pubitemid 34272700)
49. A. Rieber, H. Schirrmeister, and A. Gabelmann Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol 75 2002 789 798 (Pubitemid 35252005)
50. J.J. van der Hoeven, O.S. Hoekstra, and E.F. Comans Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer Ann Surg 236 2002 619 624 (Pubitemid 35246894)
51. M. Greco, F. Crippa, and R. Agresti Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.[see comment] J Natl Cancer Inst 93 2001 630 635 (Pubitemid 32409630)
52. D.Y. Noh, I.J. Yun, and J.S. Kim Diagnostic value of positron emission tomography for detecting breast cancer World J Surg 22 1998 223 228
53. I.C. Smith, K.N. Ogston, and P. Whitford Staging of the axilla in breast cancer - Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose Ann Surg 228 1998 220 227 (Pubitemid 30191718)
54. L.P. Adler, P.F. Faulhaber, K.C. Schnur, N.L. Al-Kasi, and R.R. Shenk Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET Radiology 203 1997 323 327 (Pubitemid 27176199)
55. N. Avril, J. Dose, and F. Janicke Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose J Natl Cancer Inst 88 1996 1204 1209 (Pubitemid 26302033)
56. C.I. Utech, C.S. Young, and P.F. Winter Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23 1996 1588 1593 (Pubitemid 27023055)
57. B.J. Pichler, H.F. Wehrl, and M.S. Judenhofer Latest advances in molecular imaging instrumentation J Nucl Med 49 Suppl. 2 2008 5S 23S (Pubitemid 351948034)
58. T. Kim, A.E. Giuliano, and G.H. Lyman Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis Cancer 106 2006 4 16 (Pubitemid 43033320)
59. R. Kumar, H. Zhuang, and M. Schnall FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer Nucl Med Commun 27 2006 231 236 (Pubitemid 44391810)
60. G. Zornoza, M.J. Garcia-Velloso, J. Sola, F.M. Regueira, L. Pina, and C. Beorlegui F-18-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer Eur J Surg Oncol 30 2004 15 19 (Pubitemid 38180986)
61. R. Agresti, F. Crippa, and A. Gerali Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches Eur J Cancer 37 2001
62. K. Yutani, E. Shiba, and H. Kusuoka Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis J Comput Assist Tomography 24 2000 274 280 (Pubitemid 32206208)
63. K. Yutani, M. Tatsumi, E. Shiba, H. Kusuoka, and T. Nishimura Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis J Nucl Med 40 1999 1003 1008 (Pubitemid 29269222)
64. P.J. Lovrics, V. Chen, and G. Coates A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer Breast Cancer Res Treat 76 2002 S129
65. F. Crippa, R. Agresti, and E. Seregni Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer J Nucl Med 39 1998 4 8 (Pubitemid 28063164)
66. E. Bombardieri, F. Crippa, and R. Agresti FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications J Nucl Med 39 1998 1119
67. F. Crippa, R. Agresti, and V.D. Donne The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan Tumori 83 1997 542 543 (Pubitemid 27314561)
68. L.P. Adler, K.C. Schnur, P.F. Faulhaber, and R.R. Shenk High sensitivity interpretation PET of the axilla: screening test for axillary lymph node metastases in patients with breast cancer Radiology 201 1996 551